Biogen (BIIB) shares down 3% following Eli Lilly & Co. (LLY) failure of solanezumab data for Alzheimer's

Biogen (BIIB) PT Lowered to $355 at Leerink Partners on Reduced Aducanumab Probability of Success

Leerink Partners analyst Geoffrey Porges reduced Aducanumab probability of success and cut his price target on Biogen (NASDAQ: BIIB) price target of $355.00 (from $365.00) after Lilly announced on Wednesday that the EXPEDITION 3 study of solanezumab (sola) in mild Alzheimer's patients did not meet its primary or secondary... More

Sola News Negative for Biogen (BIIB) as Latest in Numerous Failures for the Mechanism - Baird

Baird analyst Brian Skorney weighed in on Biogen (NASDAQ: BIIB), saying Eli Lilly's Solanezumab failure is a negative for the company.,

Skorney commented, "Lilly's registrational EXPEDITION 3 trial for solanezumab in mild Alzheimer's patients failed. Though some secondary endpoints favored sola, Lilly's admission that... More

Mizuho Sees Near-Term Trading Opportunity in Biogen (BIIB) Amid Weakness

Mizuho analyst Salim Syed weighed in on Biogen (NASDAQ: BIIB) after Eli Lilly announced this morning that its Alzheimer's drug, Solanezumab Phase 3 study has failed and it will not pursue approval which has implications to Biogen's Aducanumab.

Syed commented, "While we are... More

Sola Failure Decreases Value of Biogen's (BIIB) Aducanumab - BMO Capital

BMO Capital analyst M. Ian Somaiya weighed in on Biogen (NASDAQ: BIIB) with shares down on Eli Lilly's solanezumab's failure. The analyst said the news decreases the value of aducanumab's.

Somaiya commented, "We expect BIIB shares to trade down on solanezumab's failure, as we... More

Eli Lilly Sola Failure is a 'Serious Blow' to Biogen (BIIB) and Others in AD Field - Leerink

Leerink Partners analyst Geoffrey Porges weighed in on Biogen (NASDAQ: BIIB) after Eli Lilly (NYSE: LLY) announced that the solanezumab (sola) phase III trial in patients with mild Alzheimers disease failed to meet statistical significance on the primary endpoint and only... More